Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1Diagnosis: Breast: Early Stage DiseaseNCT ID: NCT01674842
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-283
This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have undergone breast-conserving surgery or mastectomy. Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery or mastectomy
Conducting Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, DF/BWCC at South Shore Hospital
Overall PI: Jennifer Bellon, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Steven Isakoff, MD, PhD,
Massachusetts General HospitalTatiana Lingos, MD,
Dana Farber Cancer Institute at South Shore Hospital
Contacts: Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100